ED
OCUL icon

Exane Derivatives’s Ocular Therapeutix OCUL Stock Holding History

Exane Derivatives’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,496
Closed -$19.3K – 1069
2021
Q2 		$19.3K Hold
1,496
– – ﹤0.01% 705
2021
Q1 		$24.5K Hold
1,496
– – 0.01% 557
2020
Q4 		$31K Buy
+1,496
New +$22.2K 0.01% 495

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Exane Derivatives's OCUL Position: Q3 2021 in Review

Exane Derivatives sold out of Ocular Therapeutix (OCUL) in Q3 2021, closing a stake of 1,496 shares — an estimated $19.3K sold.

Exane Derivatives first reported a position in OCUL in Q4 2020 and held it in 3 quarters. The position peaked at $31K in Q4 2020. 141 funds tracked by Wall St. Rank hold OCUL as of Q3 2021.

  • Exane Derivatives reported no remaining Ocular Therapeutix position as of Q3 2021 after selling out during the quarter.
  • Exane Derivatives sold 1,496 Ocular Therapeutix shares in Q3 2021, an estimated $19.3K.
  • Exane Derivatives first reported a position in Ocular Therapeutix in Q4 2020 and held it in 3 quarters.
  • Exane Derivatives's Ocular Therapeutix position peaked at $31K in Q4 2020.
  • 141 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2021.

Based on Exane Derivatives's 13F filing for Q3 2021, filed 26 Oct 2021.